MA51202A - Nouveaux dérivés de pipéridinyle utilisés en tant qu'inhibiteurs de la protéase 7 spécifique à l'ubiquitine - Google Patents

Nouveaux dérivés de pipéridinyle utilisés en tant qu'inhibiteurs de la protéase 7 spécifique à l'ubiquitine

Info

Publication number
MA51202A
MA51202A MA051202A MA51202A MA51202A MA 51202 A MA51202 A MA 51202A MA 051202 A MA051202 A MA 051202A MA 51202 A MA51202 A MA 51202A MA 51202 A MA51202 A MA 51202A
Authority
MA
Morocco
Prior art keywords
ubiquitine
inhibitors
specific protease
derivatives used
piperidinyl derivatives
Prior art date
Application number
MA051202A
Other languages
English (en)
Inventor
Maïa Chanrion
Olivier Geneste
Lisa Ivanschitz
Árpád Kiss
András Kotschy
Vilibald Kun
Elodie Lewkowicz
Alba Macias
Balázs Molnár
James Brooke Murray
Ágnes Strofek
Attila Vasas
Csaba Wéber
Original Assignee
Servier Lab
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Vernalis R&D Ltd filed Critical Servier Lab
Publication of MA51202A publication Critical patent/MA51202A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA051202A 2017-11-29 2018-11-28 Nouveaux dérivés de pipéridinyle utilisés en tant qu'inhibiteurs de la protéase 7 spécifique à l'ubiquitine MA51202A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1761338 2017-11-29

Publications (1)

Publication Number Publication Date
MA51202A true MA51202A (fr) 2020-10-07

Family

ID=62091951

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051202A MA51202A (fr) 2017-11-29 2018-11-28 Nouveaux dérivés de pipéridinyle utilisés en tant qu'inhibiteurs de la protéase 7 spécifique à l'ubiquitine

Country Status (17)

Country Link
US (1) US11332472B2 (fr)
EP (1) EP3717482A1 (fr)
JP (1) JP2021504388A (fr)
KR (1) KR20200094176A (fr)
CN (1) CN111542524A (fr)
AR (1) AR113846A1 (fr)
AU (1) AU2018377976A1 (fr)
BR (1) BR112020010547A2 (fr)
CA (1) CA3083320C (fr)
EA (1) EA202091260A1 (fr)
IL (1) IL274737A (fr)
MA (1) MA51202A (fr)
MX (1) MX2020005500A (fr)
RU (1) RU2020120043A (fr)
SG (1) SG11202004631RA (fr)
TW (1) TW201925202A (fr)
WO (1) WO2019105963A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118108744A (zh) * 2020-01-08 2024-05-31 四川科伦博泰生物医药股份有限公司 异噻唑并嘧啶酮类化合物，包含其的药物组合物及其用途
CN113087718B (zh) * 2020-01-09 2024-02-09 四川科伦博泰生物医药股份有限公司 噻吩并嘧啶酮类化合物及其医药应用
GB202001980D0 (en) * 2020-02-13 2020-04-01 Almac Discovery Ltd Therapeutic mentods
CN112047933B (zh) * 2020-10-15 2022-06-14 郑州大学 喹唑啉酮类usp7抑制剂及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI698436B (zh) * 2014-12-30 2020-07-11 美商佛瑪治療公司 作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶
MA41291A (fr) 2014-12-30 2017-11-07 Forma Therapeutics Inc Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
FR3052452B1 (fr) * 2016-06-10 2018-06-22 Les Laboratoires Servier Nouveaux derives de piperidinyle, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
IL274737A (en) 2020-07-30
AU2018377976A1 (en) 2020-06-04
US11332472B2 (en) 2022-05-17
WO2019105963A1 (fr) 2019-06-06
SG11202004631RA (en) 2020-06-29
TW201925202A (zh) 2019-07-01
CA3083320C (fr) 2022-08-16
AR113846A1 (es) 2020-06-17
US20200407363A1 (en) 2020-12-31
RU2020120043A (ru) 2021-12-29
CA3083320A1 (fr) 2019-06-06
JP2021504388A (ja) 2021-02-15
CN111542524A (zh) 2020-08-14
KR20200094176A (ko) 2020-08-06
EP3717482A1 (fr) 2020-10-07
MX2020005500A (es) 2020-08-31
EA202091260A1 (ru) 2020-09-07
BR112020010547A2 (pt) 2020-10-27

Similar Documents

Publication Publication Date Title
MA52486A (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA49566A (fr) Carboxamides utilisés en tant qu'inhibiteurs des canaux sodiques
MA54076A (fr) 2-amino-n-hétéroaryl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8
EP3873468A4 (fr) 2-amino-n-phényl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8
MA48994A (fr) Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
MA47120A (fr) Dérivés pyridine utilisés en tant qu'immunomodulateurs
MA51438A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA47013A (fr) Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase
MA45244A (fr) Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
MA47460A (fr) Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
MA49888A (fr) Composés macrocycliques utilisés en tant qu'inhibiteurs de kinase ros1
MA45189A (fr) Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2
MA42990A (fr) Composés utiles en tant qu'immunomodulateurs
MA42659A (fr) Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp
EP3416964A4 (fr) Dérivés de carboxamide utiles en tant qu'inhibiteurs de rsk
EP3533787A4 (fr) Composé de pyridone en tant qu'inhibiteur de c-met
EP3953331A4 (fr) Pyrazolesulfonamides en tant qu'agents antitumoraux
EP3733673A4 (fr) Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase
MA48803A (fr) Cycles 6-5 fusionnés utilisés en tant qu'inhibiteurs de c5a
MA53229A (fr) Amides de diméthyl amino azétidine utilisés en tant qu'inhibiteurs de jak
EP4013496A4 (fr) Thrombosomes en tant qu'agent désactivateur d'antiagrégant plaquettaire
MA51429A (fr) Dérivés amino-fluoropipéridines utilisés en tant qu'inhibiteur de kinase
MA50439A (fr) Nouveaux dérivés de pyrazolo-pyrrolo-pyrimidine-dione utilisés en tant qu'inhibiteurs de p2x3
MA44498A (fr) Dérivés d'indoline substituée utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue